Incyte (INCY) reported Q1 adjusted earnings Tuesday of $1.16 per diluted share, up from $0.58 a year earlier.

Analysts polled by FactSet expected $0.98.

Revenue for the quarter ended March 31 was $1.05 billion, up from $880.9 million a year earlier.

Analysts surveyed by FactSet expected $985.1 million.

The pharmaceutical company said it expects fiscal 2025 Jakafi net product revenue of $2.95 billion to $3 billion, compared with a prior outlook of $2.93 billion to $2.98 billion. Incyte continues to expect annual Opzelura net product revenue of $630 million to $670 million and other oncology net product revenue of $415 million to $455 million.

Shares of the company were 3.3% higher in recent Tuesday premarket activity.